We respond to new figures showing uptake of NHS breast screening in England reaches new decade low

Provisional data on the Breast Screening Programme England for 2017-18 were published today by NHS Digital. The new figures revealed that breast...

20 December 2018

Uptake of routine breast screening invitations at "lowest level since current programme began"

Responding to NHS Digital data revealing that uptake of routine breast screening invitations amongst women aged 50-70 has fallen to 70.5% Addie...

20 December 2018

We respond to the withdrawal from market of a type of breast implant

The French regulatory body ANSM has announced that textured breast implants made by Allergan have been withdrawn from European markets as a result of...

20 December 2018

We respond to NICE’s final guidance recommending the use of three tumour profiling tests to help some patients safely avoid chemotherapy

The National Institute for Health and Care Excellence (NICE) has today published its final updated guidance on the use of tumour profiling tests...

19 December 2018

"Life-changing" breast cancer tumour profiling tests made available

Responding to NICE final guidance that three tumour profiling tests will be available to guide adjuvant chemotherapy decisions in people with early...

19 December 2018

We respond to research suggesting ‘false positive’ result following a mammogram could indicate increased breast cancer risk

New research published today in the British Journal of Cancer has found that women who experience a ‘false positive’ result following a mammogram are...

19 December 2018

Our CEO responds to the Independent Breast Screening Review report

Responding to the publication of the Independent Breast Screening Review report, announced in May following a serious incident in the screening...

13 December 2018

Perjeta approved in Scotland for certain type of breast cancer

Responding to news that the Scottish Medical Consortium (SMC) has approved the use of pertuzumab (Perjeta) for neo-adjuvant treatment of HER2-...

10 December 2018

We respond to SMC approval of Perjeta for early breast cancer prior to surgery on NHS in Scotland

Breast Cancer Now has welcomed the Scottish Medicines Consortium’s (SMC) decision to approve breast cancer drug Perjeta (pertuzumab) as a new...

10 December 2018